BRPI0907011A8 - formulação de liberação sustentada compreendendo octreotida e três polímeros lineares de polilactpideo de coglicolídeo - Google Patents
formulação de liberação sustentada compreendendo octreotida e três polímeros lineares de polilactpideo de coglicolídeoInfo
- Publication number
- BRPI0907011A8 BRPI0907011A8 BRPI0907011A BRPI0907011A BRPI0907011A8 BR PI0907011 A8 BRPI0907011 A8 BR PI0907011A8 BR PI0907011 A BRPI0907011 A BR PI0907011A BR PI0907011 A BRPI0907011 A BR PI0907011A BR PI0907011 A8 BRPI0907011 A8 BR PI0907011A8
- Authority
- BR
- Brazil
- Prior art keywords
- polylactpide
- coglycolide
- octreotide
- polymers
- linear
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Polyesters Or Polycarbonates (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08150826 | 2008-01-30 | ||
| PCT/EP2009/051026 WO2009095450A1 (en) | 2008-01-30 | 2009-01-29 | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0907011A2 BRPI0907011A2 (pt) | 2015-07-07 |
| BRPI0907011A8 true BRPI0907011A8 (pt) | 2015-09-29 |
Family
ID=39577789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907011A BRPI0907011A8 (pt) | 2008-01-30 | 2009-01-29 | formulação de liberação sustentada compreendendo octreotida e três polímeros lineares de polilactpideo de coglicolídeo |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20110003002A1 (pt) |
| EP (1) | EP2247282B1 (pt) |
| JP (2) | JP5791278B2 (pt) |
| KR (2) | KR101921800B1 (pt) |
| CN (2) | CN104127367A (pt) |
| AU (1) | AU2009209594A1 (pt) |
| BR (1) | BRPI0907011A8 (pt) |
| CA (1) | CA2713339C (pt) |
| ES (1) | ES2522342T3 (pt) |
| MX (1) | MX2010008365A (pt) |
| PL (1) | PL2247282T3 (pt) |
| PT (1) | PT2247282E (pt) |
| RU (1) | RU2541104C2 (pt) |
| WO (1) | WO2009095450A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526700B (zh) * | 2011-12-31 | 2014-08-06 | 江苏奥赛康药业股份有限公司 | 一种注射用醋酸奥曲肽冻干组合物及其制备方法 |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| EP2823808A1 (en) * | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
| CN106727358A (zh) * | 2017-01-24 | 2017-05-31 | 广州帝奇医药技术有限公司 | 阿立哌唑及其衍生物的缓释组合物与该缓释组合物的制备方法 |
| WO2022231930A1 (en) * | 2021-04-26 | 2022-11-03 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| US20220347105A1 (en) * | 2021-04-26 | 2022-11-03 | Celanese Eva Performance Polymers Llc | Implantable Device for Sustained Release of a Macromolecular Drug Compound |
| TW202308595A (zh) * | 2021-08-13 | 2023-03-01 | 大陸商江西濟民可信集團有限公司 | 一種微球懸液、微粒製劑及其製備方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU221294B1 (en) | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| CA2316052C (en) | 1989-07-07 | 2008-09-02 | David Bodmer | Sustained release formulations of water soluble peptides |
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| DK1539101T3 (da) * | 2002-07-31 | 2009-04-27 | Alza Corp | Injicerbare, multi-modale polymere depotsammens tninger og anvendelser deraf |
| AU2003295409B2 (en) * | 2002-11-06 | 2010-02-11 | Durect Corporation | Controlled release depot formulations |
| KR100466637B1 (ko) * | 2003-06-26 | 2005-01-13 | 주식회사 펩트론 | 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법 |
| BRPI0412211A (pt) | 2003-07-23 | 2006-08-22 | Pr Pharmaceuticals Inc | composições de liberação controlada |
| MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
| KR20130024987A (ko) * | 2005-12-22 | 2013-03-08 | 노파르티스 아게 | 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제 |
-
2009
- 2009-01-29 CA CA2713339A patent/CA2713339C/en not_active Expired - Fee Related
- 2009-01-29 ES ES09705454.8T patent/ES2522342T3/es active Active
- 2009-01-29 EP EP09705454.8A patent/EP2247282B1/en active Active
- 2009-01-29 MX MX2010008365A patent/MX2010008365A/es active IP Right Grant
- 2009-01-29 RU RU2010135629/15A patent/RU2541104C2/ru active
- 2009-01-29 CN CN201410317482.3A patent/CN104127367A/zh active Pending
- 2009-01-29 US US12/865,145 patent/US20110003002A1/en not_active Abandoned
- 2009-01-29 KR KR1020167010517A patent/KR101921800B1/ko active IP Right Grant
- 2009-01-29 PL PL09705454T patent/PL2247282T3/pl unknown
- 2009-01-29 CN CN2009801025770A patent/CN101917969A/zh active Pending
- 2009-01-29 JP JP2010544702A patent/JP5791278B2/ja active Active
- 2009-01-29 KR KR1020107017006A patent/KR20100110848A/ko not_active Application Discontinuation
- 2009-01-29 AU AU2009209594A patent/AU2009209594A1/en not_active Abandoned
- 2009-01-29 BR BRPI0907011A patent/BRPI0907011A8/pt active Search and Examination
- 2009-01-29 PT PT97054548T patent/PT2247282E/pt unknown
- 2009-01-29 WO PCT/EP2009/051026 patent/WO2009095450A1/en active Application Filing
-
2012
- 2012-05-15 US US13/472,219 patent/US8999390B2/en active Active
-
2014
- 2014-12-26 JP JP2014265878A patent/JP2015107985A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2713339C (en) | 2017-01-17 |
| CA2713339A1 (en) | 2009-08-06 |
| WO2009095450A1 (en) | 2009-08-06 |
| JP2015107985A (ja) | 2015-06-11 |
| CN101917969A (zh) | 2010-12-15 |
| KR20160052756A (ko) | 2016-05-12 |
| RU2010135629A (ru) | 2012-03-10 |
| US8999390B2 (en) | 2015-04-07 |
| PL2247282T3 (pl) | 2015-03-31 |
| JP2011510951A (ja) | 2011-04-07 |
| KR101921800B1 (ko) | 2018-11-23 |
| CN104127367A (zh) | 2014-11-05 |
| BRPI0907011A2 (pt) | 2015-07-07 |
| JP5791278B2 (ja) | 2015-10-07 |
| AU2009209594A1 (en) | 2009-08-06 |
| MX2010008365A (es) | 2010-08-23 |
| EP2247282A1 (en) | 2010-11-10 |
| US20120226224A1 (en) | 2012-09-06 |
| ES2522342T3 (es) | 2014-11-14 |
| PT2247282E (pt) | 2014-11-11 |
| EP2247282B1 (en) | 2014-08-20 |
| US20110003002A1 (en) | 2011-01-06 |
| RU2541104C2 (ru) | 2015-02-10 |
| KR20100110848A (ko) | 2010-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE518527T1 (de) | Rasagilinformulierung mit verzögerter freisetzung | |
| BRPI0908596A2 (pt) | formulação e composição farmacêutica de liberação prolongada | |
| BRPI0914630A2 (pt) | liberação dérmica | |
| BRPI0922989A2 (pt) | Liberação sustentada de nutrientes in vivo | |
| BRPI0918652A2 (pt) | Composições farmacêuticas e métodos de libração relacionadas. | |
| DE112009000905A5 (de) | Implantierbare Nanopartikel-enthaltende Produkte | |
| BRPI0918499A2 (pt) | polímeros reticulados | |
| BRPI0918734A2 (pt) | material polimérico | |
| BRPI0909780A2 (pt) | Composições e métodos para liberação de fármaco | |
| BRPI0921822A2 (pt) | composição compreendendo polímero e enzima | |
| BRPI0917358A2 (pt) | formulação farmacêutica de liberação controlada e método. | |
| EP2308910A4 (en) | POLYMER COMPOUND AND PHOTOEMETER ELEMENT USING THE SAME | |
| EP2244782A4 (en) | POLYMER FOR LINEAR RELEASE | |
| EP2274043A4 (en) | BIODEGRADABLE METAL-CHELATING POLYMERS AND VACCINES | |
| BRPI0918904A2 (pt) | formulações de liberação sustentada usando carreadores não aquosos | |
| BRPI0721969A2 (pt) | regime de dosagem de ibuprofeno de liberação imediata e de liberação sustentada | |
| EP2257427A4 (en) | LASER-POLYMER MATERIALS | |
| PL2086567T3 (pl) | Formulacje o przedłużonym uwalnianiu zawierające polimery o bardzo niskim ciężarze cząsteczkowym | |
| BRPI0914651A2 (pt) | conjunto de cunha e soquete | |
| BRPI0907011A8 (pt) | formulação de liberação sustentada compreendendo octreotida e três polímeros lineares de polilactpideo de coglicolídeo | |
| BRPI0921654A2 (pt) | formulação farmacêutica | |
| SE0801651L (sv) | Granuleringskvarn | |
| BRPI0912428A2 (pt) | formulação farmacêutica sólida de liberação retardada | |
| BRPI0922423A2 (pt) | dispositivo de liberação de fármaco | |
| BRPI0811732A2 (pt) | Formulação de liberação prolongada de nevirapina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |